Logo image of LRMR

LARIMAR THERAPEUTICS INC (LRMR) Stock Fundamental Analysis

NASDAQ:LRMR - Nasdaq - US5171251003 - Common Stock

3.44  +0.01 (+0.29%)

Fundamental Rating

3

Taking everything into account, LRMR scores 3 out of 10 in our fundamental rating. LRMR was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LRMR as it has an excellent financial health rating, but there are worries on the profitability. LRMR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LRMR has reported negative net income.
LRMR had a negative operating cash flow in the past year.
In the past 5 years LRMR always reported negative net income.
In the past 5 years LRMR always reported negative operating cash flow.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

LRMR has a Return On Assets of -29.57%. This is in the better half of the industry: LRMR outperforms 69.56% of its industry peers.
LRMR has a Return On Equity of -32.65%. This is in the better half of the industry: LRMR outperforms 77.35% of its industry peers.
Industry RankSector Rank
ROA -29.57%
ROE -32.65%
ROIC N/A
ROA(3y)-43.61%
ROA(5y)-45.54%
ROE(3y)-51.91%
ROE(5y)-57.56%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

LRMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

LRMR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LRMR has more shares outstanding
LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 4.80 indicates that LRMR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 4.80, LRMR belongs to the best of the industry, outperforming 80.89% of the companies in the same industry.
There is no outstanding debt for LRMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.8
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

LRMR has a Current Ratio of 13.10. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LRMR (13.10) is better than 86.02% of its industry peers.
LRMR has a Quick Ratio of 13.10. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LRMR (13.10) is better than 86.19% of its industry peers.
Industry RankSector Rank
Current Ratio 13.1
Quick Ratio 13.1
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

LRMR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.32%.
EPS 1Y (TTM)-51.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LRMR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-45.96%
EPS Next 2Y-37.9%
EPS Next 3Y-35.46%
EPS Next 5Y11.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LRMR. In the last year negative earnings were reported.
Also next year LRMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

LRMR's earnings are expected to decrease with -35.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-37.9%
EPS Next 3Y-35.46%

More info and screens

0

5. Dividend

5.1 Amount

LRMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (1/22/2025, 10:45:17 AM)

3.44

+0.01 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)N/A N/A
Inst Owners108.11%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change0%
Market Cap219.51M
Analysts89.41
Price Target21.93 (537.5%)
Short Float %8.07%
Short Ratio5.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.04%
Min EPS beat(2)-9.17%
Max EPS beat(2)37.25%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-18.88%
Max EPS beat(4)37.25%
EPS beat(8)5
Avg EPS beat(8)9.19%
EPS beat(12)9
Avg EPS beat(12)12.02%
EPS beat(16)10
Avg EPS beat(16)5.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.83%
PT rev (3m)-2.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.52%
EPS NY rev (1m)0%
EPS NY rev (3m)13.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.11
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.57%
ROE -32.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.61%
ROA(5y)-45.54%
ROE(3y)-51.91%
ROE(5y)-57.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.1
Quick Ratio 13.1
Altman-Z 4.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.33%
Cap/Depr(5y)102.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-45.96%
EPS Next 2Y-37.9%
EPS Next 3Y-35.46%
EPS Next 5Y11.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-101.57%
EBIT Next 3Y-51.37%
EBIT Next 5Y29.81%
FCF growth 1Y-103.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.23%
OCF growth 3YN/A
OCF growth 5YN/A